Dr John O’Donnell

Senior Vice-President & Head of Research, Innoviva Specialty Therapeutics

John O’Donnell has over 30 years of pharmaceutical research and development experience.  Prior to Innoviva Specialty Therapeutics he headed up the department of Drug Metabolism and Pharmacokinetics for Entasis where he was heavily involved with the development of Xacduro supporting the pharmacology, PK/PD, and ultimately the dose justification leading into the Phase 3 clinical trial.  Prior to Entasis he headed up pharmacology departments at Pfizer and AstraZeneca within their respective infection portfolios.  He currently leads discovery efforts at Innoviva Specialty Therapeutics with a team of medicinal chemistry, biology, and drug metabolism scientists.